Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
results implicate Eya4/Six1 (show SIX1 Proteins) regulates normal cardiac function via p27 (show CDKN1B Proteins)/casein kinase-2alpha/histone deacetylase 2 (show HDAC2 Proteins) and indicate that mutations within this transcriptional complex and signaling cascade lead to the development of cardiomyopathy.
constructs of the homologous region ( Eya1HR and Eya4HR) interact with Six1 (show SIX1 Proteins) prey constructs, although no interaction with Dach1 (show DACH1 Proteins) prey was demonstrable
Eya4(-/-) mice developed otitis media with effusion; anatomic studies revealed abnormal middle ear cavity and eustachian tube dysmorphology.
that Eyes absent 4 (EYA4), originally identified as a co-transcription factor, stimulates the expression of IFN-beta (show IFNB1 Proteins) and CXCL10 (show CXCL10 Proteins) in response to the undigested DNA of apoptotic cells
EYA4 hypermethylation is associated with colorectal cancer.
EYA4 functions as tumor suppressor gene in pancreatic ductal adenocarcinoma via repressing beta-catenin/ID2 activation, and was an independent prognostic factor in PDAC.
Low expression of EYA4 is associated with oral cancer.
We discovered two genome-wide significant SNPs. The first was novel and near ISG20 (show ISG20 Proteins). The second was in TRIOBP, a gene previously associated with prelingual nonsyndromic hearing loss. Motivated by our TRIOBP results, we also looked at exons in known hearing loss genes, and identified two additional SNPs, rs2877561 in ILDR1 (show ILDR1 Proteins) and rs9493672 in EYA4 (at a significance threshold adjusted for number of SNPs in those regions).
Up to now, merely 7 loci have been linked to mid-frequency hearing loss. Only four genetic mid-frequency deafness genes, namely, DFNA10 (EYA4), DFNA8/12 (TECTA), DFNA13 (COL11A2), DFNA44 (CCDC50 (show CCDC50 Proteins)), have been reported to date. [review]
study identified EYA4 gene as targets for AML1 (show RUNX1 Proteins)-ETO (show RUNX1T1 Proteins) and indicated it as a novel tumor suppressor gene. In addition, we provided evidence that EYA4 gene might be a novel therapeutic target and a potential candidate for treating AML1 (show RUNX1 Proteins)-ETO (show RUNX1T1 Proteins)+ t (8;21) AML (show RUNX1 Proteins).
Loss of EYA4 expression is associated with intrahepatic cholangiocarcinoma.
The identification of a novel EYA4 truncation mutation associated with DFNA10, rather than syndromic hearing loss, supports a previously reported genotype-phenotype correlation in this gene.
results implicate Eya4/Six1 (show SIX1 Proteins) regulates normal cardiac function via p27 (show PAK2 Proteins)/casein kinase-2alpha/histone deacetylase 2 (show HDAC2 Proteins) and indicate that mutations within this transcriptional complex and signaling cascade lead to the development of cardiomyopathy.
In a Dutch family with c.464del EYA4 mutation, hearing impairment begins as a mid-frequency hearing impairment in childhood and develops into a high-frequency, moderate hearing impairment later in life.
This gene encodes a member of the eyes absent (EYA) family of proteins. The encoded protein may act as a transcriptional activator through its protein phosphatase activity, and it may be important for eye development, and for continued function of the mature organ of Corti. Mutations in this gene are associated with postlingual, progressive, autosomal dominant hearing loss at the deafness, autosomal dominant nonsyndromic sensorineural 10 locus. Defects in this gene are also associated with dilated cardiomyopathy 1J. Three transcript variants encoding distinct isoforms have been identified for this gene.
eyes absent homolog 4
, dJ78N10.1 (eyes absent)
, eyes absent 4